aibioBioForce Nanosciences names interim CEO, adds general counsel and advisers
Tickers BFNH
An August 14, 2026 filing lists officers, directors and advisory board members, including Richard Kaiser as interim chief executive officer and Scott Mager as general counsel and director.
Key facts
- Company
- BIOFORCE NANOSCIENCES HOLDINGS, INC. (OTC: BFNH)
- News type
- Company Updates
- Primary source
- Form 8-K (SEC EDGAR)
BioForce Nanosciences Holdings, Inc. filed a Form 8-K on August 14, 2026 that lists its officers, directors and advisory board members. The filing is a voluntary disclosure under Item 8.01 and is signed by Richard Kaiser, the company's interim chief executive officer. The company is based in Virginia Beach, Virginia, and is incorporated in Nevada.
Officers and directors
The table in the filing lists Merle Ferguson as a director, Richard Kaiser as director, interim chief executive officer, chief financial officer and secretary, and Scott Mager as a director. On June 17, 2026, the board appointed Kaiser as interim chief executive officer. The filing says Kaiser has been an officer and director of the company since July 1, 2013, and that he continues in his roles as chief financial officer, secretary and director.
On May 19, 2026, the board appointed Mager, an attorney from Ft. Lauderdale, Florida, as general counsel under a three-year contract. On June 15, 2026, the board appointed him as a director. The filing says there are no arrangements or understandings between him and any other person under which he was selected as a director, and no related party transactions with him that would require disclosure under Item 404(a) of Regulation S-K.
The filing says Mager graduated from Nova Southeastern Law School in 1988 and is licensed in multiple states. The filing says he has been named National Litigator of the Year by a multi-billion-dollar corporate conglomerate, which it does not name, and that he has published or lectured on complex legal and business issues in over 150 articles.
Advisory board
On May 19, 2026, the company established an advisory board. Stuart Yarbrough and Edward Mathias accepted advisory board positions. Each position is a three-year term ending May 19, 2029. The filing does not describe their duties.
Yarbrough is an active private investor. The filing says he spent over 20 years in public accounting, primarily with Ernst & Young and BDO Seidman, and then served as chief executive partner of 3Point Capital Partners, a firm he co-founded. It says 3Point provided investment banking services and venture debt financing to growth companies and closed merger and sale transactions with a total value in excess of $2.5 Billion.
Mathias is a senior advisor to The Carlyle Group, the alternative asset management firm. The filing says he helped form Carlyle, assisted in raising its initial capital, and joined the firm full-time in 1992. Before that he spent over 20 years at T. Rowe Price Associates, Inc., including on its Management Committee and Board of Directors.
Financial position
SEC XBRL data summarizes figures the company reported in its annual report on Form 10-K, filed April 15, 2026, and in a quarterly report on Form 10-Q. For the fiscal year ended December 31, 2025, the company reported a net loss of $1.3 million, compared with a net loss of $490,437 for 2024. Cash from operations was negative $65,150 in 2025 and negative $61,250 in 2024. Year-end cash and cash equivalents were $786 for 2025 and $862 for 2024. At June 30, 2026, cash and cash equivalents were $307, according to the 10-Q.
What the filing does not say
The credentials are the company's own description and the filing gives no way to check them. The company reports $307 in cash at June 30, 2026, so the filing does not explain how it will pay a general counsel on a three-year contract or any advisers, and it states no compensation. It describes no products, revenue or business plan, and it names no reason for adding a general counsel and an advisory board, so the appointments say little about operations. The company's stock has no exchange listing in the filing, which shows no securities registered under Section 12(b). The filing says all directors hold office until the next annual meeting of stockholders or until their successors are elected and qualified. The advisory board terms run to May 19, 2029, and the general counsel contract runs for three years from its May 19, 2026 start. The filing does not give a timetable for further changes to the board or management.